The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the neutrophil−lymphocyte ratio (NLR) and early NLR changes with survival in ICI-tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2022-08, Vol.11 (15), p.4523
Hauptverfasser: Guven, Deniz Can, Sahin, Taha Koray, Erul, Enes, Cakir, Ibrahim Yahya, Ucgul, Enes, Yildirim, Hasan Cagri, Aktepe, Oktay Halit, Erman, Mustafa, Kilickap, Saadettin, Aksoy, Sercan, Yalcin, Suayib
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Cancer therapies
Clinical medicine
Clinical trials
Ethics
Immunotherapy
Kidney cancer
Laboratories
Lymphocytes
Medical prognosis
Melanoma
Metastasis
Neutrophils
Patients
Tumors
Variables
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the neutrophil−lymphocyte ratio (NLR) and early NLR changes with survival in ICI-treated patients. We retrospectively evaluated the data of 231 patients with advanced-stage cancer. We recorded baseline clinical characteristics, baseline NLR and fourth-week NLR changes, and survival data. A compound prognostic score, the NLR2-CEL score, was developed with the following parameters: baseline NLR (
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11154523